Novel NTRK1 fusion molecules, detection reagents, and uses and kits for evaluating, identifying, assessing and/or treating a subject having a cancer are disclosed.

Novel NTRK1 fusion molecules, detection reagents, and uses and kits for evaluating, identifying, assessing and/or treating a subject having a cancer are disclosed.

This application relates to combination compositions for use in treatment of depression, and which can alleviate the anxiogenic side effects of certain antidepressant and antipsychotic medications. Methods for treatment of depression and medicament side effects, particular anxiety, akathisia, and associated suicidality are also described herein.

This application relates to combination compositions for use in treatment of depression, and which can alleviate the anxiogenic side effects of certain antidepressant and antipsychotic medications. Methods for treatment of depression and medicament side effects, particular anxiety, akathisia, and associated suicidality are also described herein.

This application relates to combination compositions for use in treatment of depression, and which can alleviate the anxiogenic side effects of certain antidepressant and antipsychotic medications. Methods for treatment of depression and medicament side effects, particular anxiety, akathisia, and associated suicidality are also described herein.

The present disclosure relates to a method of treating a glioblastoma by conjointly administering to a subject a BCL-xL inhibitor and a second therapy such as an alkylating agent, irradiation, or an MCL-1 inhibitor.

The present disclosure relates to a method of treating a glioblastoma by conjointly administering to a subject a BCL-xL inhibitor and a second therapy such as an alkylating agent, irradiation, or an MCL-1 inhibitor.

Compounds having the formula I wherein R.sup.1, X.sup.1, X.sup.2, X.sup.3 and X.sup.4 as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders.

##STR00001##

Compounds having the formula I wherein R.sup.1, X.sup.1, X.sup.2, X.sup.3 and X.sup.4 as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders.

##STR00001##

This invention provides methods utilizing ketamine for the treatment of motor disorders and/or side effects associated with certain medications used in the treatment of motor disorders. For example, in some embodiments, methods are provided for treating side effects associated with the administration of levodopa to a subject having Parkinson's disease, by administering a dose of ketamine or a pharmaceutically acceptable salt thereof. In particular, the invention provides methods for reducing dyskinesia associated with motor disorder (e.g., Parkinson's disease) treatments, and effective doses of ketamine or a pharmaceutically acceptable salt